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Abstract
Histamine H3 receptor therapeutics have been proposed for several diseases such
as schizophrenia, attention deficit hyperactivity disorder, Alzheimer’s disease and
obesity. We set out to evaluate the novel compound, [125I]WYE-230949, as a
potential radionuclide imaging agent for the histamine H3 receptor in brain.
[125I]WYE-230949 had a high in vitro affinity for the rat histamine H3 receptor (Kd of
6.9 nM). The regional distribution of [125I]WYE-230949 binding sites in rat brain,
demonstrated by in vitro autoradiography, was consistent with the known
distribution of the histamine H3 receptor. Rat brain uptake of intravenously injected
[125I]WYE-230949 was low (0.11 %ID/g) and the ratio of specific: non-specific
binding was less than 1.4, as determined by ex vivo autoradiography. In plasma,
metabolism of [125I]WYE-230949 into a less lipophilic species occurred, such that
less than 38% of the parent compound remained 30 minutes after injection. Brain
uptake and metabolism of [125I]WYE-230949 were increased and specific binding
was reduced in anaesthetised compared to conscious rats. [125I]WYE230949 is not
a potential radiotracer for imaging rat histamine H3 receptors in vivo due to low
brain uptake, in vivo metabolism of the parent compound and low specific binding.
Introduction
Histamine is a neurotransmitter in the central nervous system that regulates its
own release and synthesis via a presynaptic G-protein-coupled histamine H3
autoreceptor [1]. The histamine H3 receptor also acts as a heteroreceptor
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regulating other neurotransmitters, such as acetylcholine [2, 3], noradrenaline [4],
dopamine [5] and serotonin [6]. There is evidence for histamine H3 receptor
dysregulation in several diseases, including Alzheimer’s disease and vascular
dementia where a negative correlation between fronto-cortical H3 receptor density
and cognitive decline exists [7, 8]. There is increased histamine H3 receptor
binding in the substantia nigra of patients with Parkinson’s disease and in the
prefrontal cortex of schizophrenic patients [9, 10] and histamine H3 receptor
knock-out worsens multiple sclerosis symptoms in a mouse model [11]. Currently
there are several histamine H3 antagonist/inverse agonists in Phase II and III
clinical trials for conditions such as excessive daytime sleepiness in Parkinson’s
disease; cognitive dysfunction in attention deficit hyperactivity disorder,
schizophrenia and Alzheimer’s disease; and metabolic dysfunction in obesity and
diabetes mellitus (reviewed in [12, 13]). However the role of histaminergic brain
networks in disease is still poorly understood as highlighted in a recent review
which calls for further analysis into histamine receptor expression in specific
neural pathways [14]. To this end a readily available radiopharmaceutical which
could longitudinally measure histamine H3 receptor expression in different
disease states would be useful.
Several attempts have been made to develop single photon emission computed
tomography (SPECT) and positron emission tomography (PET) radiotracers for
the histamine H3 receptor (reviewed in [15]). However until recently translation
into human studies has proved difficult due to a number of factors. The
development of SPECT radiotracers for the histamine H3 receptor has had limited
success. [123I]GR190028 and [123I]FUB271 have high hepatic and pulmonary
uptake, while [123I]iodoproxyfan binds to a non-H3 receptor binding site [16] and
[123I]iodophenpropit does not readily enter the brain [17]. A meta-iodo
substituted benzophenone derivative (4-(3-(1H-imidazol-4-yl)propyloxy)phenyl
3-iodophenyl methanone) was described with nanomolar affinity for the
histamine H3 receptor, but to our knowledge has not been taken forward for
further development [18].
In particular, for PET imaging, thioperamide analogues [18F]VUF5000 and
[18F]VUF5182 exhibited very low brain uptake: less than 0.02%ID/g [19].
[11C]JNJ-10181457 had low specific binding possibly due to its binding affinity
being in the high nanomolar range [20]. [18F]Fluoroproxyfan bound hetero-
geneously in the rat brain, and striatal, thalamic and hypothalamic binding was
displaceable by unlabeled fluoroproxyfan in vivo, although cortical binding was
not displaced [21]. [18F]Merck 2b and [18F]9 ([18F]XB-1) have shown promise in
mouse and monkey models but have not as yet been take forward into clinical
assessment [22, 23]. Recently, two carbon-11 radiotracers have successfully been
used in clinical trials. [11C]GSK189254 has been used to quantify histamine H3
receptor availability in humans [24] and to monitor the target engagement and
pharmacokinetics of a number of H3 antagonists in humans and primates
[25, 26, 27]. [11C]MK8278 (formerly [11C]Merck 1b) has been used in the clinical
development of histamine H3 inverse agonists [23, 28].
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Although carbon-11 radiotracers have shown utility assessing H3 drug
candidates in early phase clinical trials, carbon-11, with a 20 minute half-life,
cannot be widely distributed due to the requirement for onsite cyclotron facilities.
Radionuclides with longer half-lives such as 123I for SPECT (tK 13.2 hours) or
124I for PET (tK 4.18 days) could allow wider investigation into H3 dysregulation
potentially advancing understanding of the role of H3 histamine receptors in
disease.
We aimed to evaluate [125I]WYE-230949 as a potential radionuclide imaging
agent for the histamine H3 receptor. WYE-230949 (Fig. 1) is a benzimidazole-
substituted 1,39-bipyrrolidine benzamide, a group of compounds that have been
shown to act as high affinity antagonists at human histamine H3 receptors and
1000-fold selectivity for human histamine H3 over H1 and H2 receptors [29, 30].
WYE-230949 contains an iodine in the 79 position of the imidazole ring, has a Ki
for human and rat histamine H3 receptors of 0.3 nM and 5.7 nM respectively, and
a molecular structure suitable for radioiodination [29, 31]. To control for the
effects of isoflurane anaesthesia on radiotracer uptake we performed studies in
anesthetised and conscious animals. We present here the in vitro, ex vivo and in
vivo evaluation of [125I]WYE-230949 in rats.
Materials and Methods
Reagents
Sodium [125I]iodide in dilute (0.1 M) NaOH was purchased from Perkin Elmer
Life and Analytical Sciences, Boston, MA (specific activity 81.76GBq/mM);
iodophenpropit dihydrobromide was purchased from Tocris Bioscience, Bristol,
UK. Other reagents and chemicals were purchased from Riedel de Hae¨n, Seelze,
Germany and Sigma-Aldrich, Gillingham, UK, and were used without further
purification. WYE230949 and the tributylstannyl precursor of WYE-230949 were
obtained from Wyeth Research, Princeton, NJ.
HPLC
Analytical high performance liquid chromatography (HPLC) was performed on a
reverse-phase C18 analytical column (4 mm, 4.6 mm6150 mm; Synergi Hydro;
Phenomenex, Macclesfield, UK) with 10 mm guard cartridge, UV 254 nm and
flow 1 ml/min. Radiodetection was carried out using a Radiomatic 500R series or
a Berthold Flowstar LB513 radiodetector (Berthold Technologies, Harpenden,
UK). Preparative HPLC was performed on a reverse-phase C18 semi-preparative
column (4 mm, 10 mm6150 mm; Synergi Hydro; Phenomenex) with 10 mm
guard cartridge, UV 254 nm and flow 3 ml/min. Radiodetection was carried out
using a Bioscan Flowcount (Bioscan Inc, Washington, DC) radiodetector.
Analytical and preparative HPLC were run in either 0.1% trifluoroacetic acid in
water/0.1% trifluoroacetic acid in acetonitrile or 0.1% trifluoroacetic acid in
water/0.1% trifluoroacetic acid in methanol.
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Radiolabelling of WYE-230949
The radiolabelling of WYE-230949 has previously been reported [31]. Briefly, to a
V-vial containing 74–370 MBq of Na[125I] made up to 50 ml with 0.05 M NaOH
was added 20 ml of 1 M HCl, 0.3 mg of the tributylstannyl precursor of WYE-
230949 in 100 ml ethanol, and 50 ml chloramine-T solution (1 mg/ml). The
reaction was mixed via vortex and incubated at room temperature for 5 min, after
which it was quenched by addition of 200 ml of mobile phase. The reaction
mixture was analysed by analytical HPLC before purification by preparative
HPLC. The fraction containing the desired product was collected and the solvent
was removed by rotary evaporation. The product was reconstituted with 0.9%
saline, and finally passed through a 0.22 mm filter. The radiochemical purity was
determined by analytical HPLC and the specific activity of the final product was
calculated using a concentration-response curve obtained using the corresponding
cold standard.
For in vitro studies, carrier WYE-230949 was added in order to obtain the
higher concentration of WYE-230949 required for Kd determination. Unlabelled
WYE-230949 was added prior to purification by preparative HPLC in order to
allow the accurate measurement of specific activity from the preparative HPLC
trace. For in vivo studies of [125I]WYE-230949, 6 mg ascorbic acid was added to
during the formulation and the radioligand prepared as described above stored in
a refrigerator and protected from light until use.
Fig. 1. Chemical Structure of WYE-230949.
doi:10.1371/journal.pone.0115876.g001
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Determination of the partition and distribution co-efficients (logP
and logD)
The lipophilicity of [125I]WYE-230949 was determined in octanol/water and at
physiological pH using a modification of the shake-flask method [32]. Briefly,
[125I]WYE-230949 was mixed with 1 ml of octanol and 1 ml of water (for logP) or
with 1 ml of octanol and phosphate buffer (100 mM, pH 7.4). The radioactivity
incorporated in both phases was determined using a gamma counter (Cobra
Gamma Counter, Packard, Perkin Elmer Life and Analytical Sciences, Boston,
MA, USA). The assay was performed in triplicate on 3 separate occasions. LogP
was calculated to be log [counts in octanol/counts in water] and logD was
calculated to be log [counts in octanol/counts in pH 7.4 buffer].
In vitro radioligand binding
Animals (male Sprague-Dawley rats; Harlan, UK) were killed by cervical
dislocation. Whole brains were immediately excised and placed into ice-cold Tris-
HCl buffer (Tris 50 nM, pH 7.4; EDTA 5 mM), homogenised and centrifuged at
approx 40,000 g for 10 min at 4 C˚ (Beckman J2-21M/E). The pellet was
resuspended in 25 ml of buffer and centrifuged as previously, then the final pellet
was resuspended in 10 ml of ice cold Tris buffer and stored at 250 C˚ until
required. Protein content was analysed using Bio-Rad reagent; absorbance was
read on a spectrophotometer at 562 nm [33]. [125I]WYE230949 binding assays
were carried out in a final incubation volume of 500 ml containing Tris-HCl
buffer (Tris 50 nM, pH 7.4; EDTA 5 mM), brain homogenates (1.47 to 2.27 mg/
ml of protein) and [125I]WYE230949 (0.04–102 nM). Non-specific binding was
defined in the presence of 10 mM iodophenpropit. Samples were incubated at
30 C˚ for 30 min, then filtered rapidly through Whatman GF/B filters (pre-treated
with 0.3% polyethylenimine; Aldrich, UK) using a Brandel M24R cell harvester
and the filters washed with 364 ml ice-cold Tris buffer. Radioactivity on the
filters was determined by liquid scintillation counting a minimum of 48 h after
filtration. All assays were performed in triplicate. Specific binding was determined
by subtracting non-specific binding from total binding at each concentration; Kd
and Bmax values derived using GraphPad Prism (version 4.03), and expressed as
mean ¡SEM of the triplicate assays.
In vivo administration of [125I]WYE-230949
Animal experiments were conducted under the UK Animals (Scientific
Procedures) Act 1986. This work was approved by the ethical review committee at
the University of Glasgow (PPL: 60/3436) prior to the start of study. Nai¨ve male
Sprague-Dawley rats (Harlan, UK), weighing 217 to 352 g were either conscious
or anaesthetised (2.5–3% isoflurane via a tracheostomy and artificial ventilation in
70/30% N2O/O2) for the duration of the experiment. Anaesthetised rats had their
respiration and temperature monitored throughout. [125I]WYE-230949 was
administered via a femoral vein cannula to anaesthetised rats or via the lateral tail
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vein to conscious rats. The injected dose for each rat was calculated by measuring
the syringe in a dose calibrator before and after [125I]WYE-230949 administration.
The radioactive and radiochemical amounts administered to individual rats
ranged from 12.6 to 24.5 MBq and 0.32 to 0.70 mg/kg respectively in all in vivo
studies.
In vivo microSPECT imaging
MicroSPECT imaging was performed in order to image the uptake of [125I]WYE-
230949 in the brain over time. SPECT scanning was performed using a MollyQ 50
microSPECT scanner (Neurophysics Corp., Shirley, MA, U.S.A.). Rats were
anaesthetised for the duration of scan (2–3% isoflurane in 70/30% N2O/O2) and
physiological parameters were maintained as described previously [34]. The
scanning protocol was designed to ensure that a forebrain slice encompassing
structures dense in H3 bindings sites including cortex, striatum, hippocampus and
thalamus was captured; the first slice being 14.4 mm caudal to the eyes,
approximately at the level of the caudate nucleus. Scanning was commenced
12 min prior to intravenous injection of [125I]WYE-230949 via the tail vein. Ten
sequential coronal slices (400 mm/slice) were collected over a total scanning
distance of 4 mm with a scanning time of 12 min per repetition. This protocol
was repeated over the same 4 mm slice for a total of 17 repetitions. SPECT images
were co-registered with corresponding T2-weighted MRI images obtained from a
strain- and weight-matched rat using anatomical landmarks from a previously
registered whole brain scan. MRI was carried out on a Bruker Biospec 7T using a
T2-weighted sequence with an isotropic resolution of 300 mm. The MR image set
was manually aligned to the SPECT images set using AMIDE (A Medical Image
Data Examiner) freeware. Each post injection SPECT stack was compiled to
produce a 170 slice stack of the entire scan over time using Image J freeware (NIH,
USA). In order to determine whole brain uptake a region of interest (ROI)
encompassing cortical, striatal, hippocampal and thalamic structures was defined
using anatomical information on the MRI data set. The mean intensity of the ROI
in each slice of the SPECT images was measured by plotting a z-axis profile. These
were averaged over 12 minute time bins to produce a mean intensity for the entire
4 mm slice. These were converted to emissions per second per mm3 using the scan
scaling factor and then to disintegrations per second per ml or Bq/ml. Finally
these values were expressed as % of injected dose per ml of tissue and plotted
against time.
Ex vivo biodistribution
Ex vivo biodistribution studies were performed in both conscious and
anaesthetised rats in order to investigate the effect of anaesthesia on [125I]WYE-
230949 uptake. At 30 or 120 min following [125I]WYE-230949 administration rats
were killed by cervical dislocation. These time points were chosen based on the
biological half life of [125I]WYE-230949 determined from microSPECT imaging
Assessment of a Novel H3 Receptor Tracer
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studies. Serial arterial blood sampling via a femoral artery cannula was performed
in anaesthetised rats only. Blood was collected into heparin-coated tubes for
analysis of plasma and into EDTA coated tubes for analysis of whole blood. At
either 30 or 120 min following [125I]WYE-230949 administration rats were killed
by cervical dislocation and the brain, heart, lungs, kidneys and liver dissected.
Samples were counted on a Gamma Scintillation Counter (Packard Cobra II
D5010, UK) and counts per minute (cpm) converted to kBq using a standard
curve. Radioactivity was corrected for decay of 125I and expressed per sample
weight and as a percentage of injected dose (%ID/g tissue).
Ex vivo autoradiography
Regional brain uptake was determined by ex vivo autoradiography, studies were
performed in both conscious and anaesthetised rats in order to investigate the
effect of anaesthesia on [125I]WYE-230949 uptake. At either 30 or 120 min
following [125I]WYE-230949 administration rats were killed by cervical disloca-
tion. The brains were removed, frozen in isopentane at 242 C˚ and stored at
220 C˚ before sectioning (20 mm) in a cryostat (Bright Instrument Company Ltd).
Three sections were taken every 400 mm for the entire length of the rat brain and
thaw mounted onto poly-L-lysine coated slides. Sections were dried at room
temperature and apposed to X-ray film (Kodak Biomax MR-1) for approximately
2 weeks. The resultant autoradiograms were analysed using computer-based
densitometry (MCID, Imaging Research, Canada). Relative optical density (ROD)
measurements were obtained from 14 ROIs defined with reference to a rat brain
atlas [35]. For each brain region examined, bilateral readings were obtained in
triplicate and the average reading determined. ROD values in the cerebellum were
used as a measure of non-specific binding. Specific binding was calculated as ROD
in ROI/ROD in cerebellum.
In vitro autoradiography
Sections (20 mm) cut from a frozen rat brain were pre-incubated in Tris-HCl
buffer (50 mM, pH 7.4; EDTA 5 mM) for 15 min then incubated in 5 nM
[125I]WYE-230949 for 90 min at room temperature. Non-specific binding was
defined in adjacent sections in the presence of 5 mM iodophenpropit
dihydrobromide. Sections were washed (2630 min in Tris buffer) and briefly
(15 s) rinsed in distilled water before drying and apposition to Kodak Biomax for
24 h. These autoradiograms were generated only for visual comparison with those
obtained ex vivo.
E vivo analysis of rat plasma and brain samples
After intravenous injection of [125I]WYE-230949 blood samples were obtained by
terminal cardiac puncture from anaesthetised rats or via the lateral tail vein from
conscious rats at either 30 or 120 min. Rats were then immediately killed by
Assessment of a Novel H3 Receptor Tracer
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cervical dislocation and the brain removed. Plasma was separated from whole
blood by centrifugation and the protein precipitated by combining 400 ml of
plasma with 400 ml of ice-cold acetonitrile. A sample (200 ml) of the supernatant
was made up to 1 ml with distilled water and injected onto the HPLC column.
The brain was homogenised in 2 ml saline, protein precipitated by addition of
2 ml of ice-cold acetonitrile. Samples were then centrifuged (1300 rpm; 2006g)
and the supernatant added to 1 ml acetonitrile before being centrifuged again
(1300 rpm; 2006g). The acetonitrile was evaporated under a stream of argon gas
and the remaining 1 ml injected onto the HPLC column. Analysis of the brain and
plasma metabolite samples was performed using the analytical HPLC methodol-
ogy described. The % parent compound present was calculated.
Statistical analysis
All data are presented as mean ¡SEM. Data obtained at 30 and 120 min in
conscious and anaesthetised groups were compared using two-way ANOVA with
time and anaesthesia as variables with a single rat as the unit of analysis.
Results
Radiochemistry
[125I]WYE-230949 was synthesized with an isolated radiochemical yield of
50.7¡1.7% (n522). For in vivo and ex vivo experiments, [125I]WYE-230949 was
synthesised with specific activity 82.9¡7.4 GBq/mmol (n514). For in vitro
experiments, [125I]WYE-230949 was synthesised with a lower specific activity of
8.5¡1.1 GBq/mmol (n55) due to the addition of carrier needed to obtain the
WYE-230949 concentration required for Kd determination. HPLC analysis
showed that [125I]WYE-230949 had.99% radiochemical purity.
Partition and distribution co-efficients (logP and logD)
The experimentally determined logP and logD7.4 values for [
125I]WYE-230949
were 1.59¡0.04 (n53) and 1.64¡0.04 (n53) respectively.
In vitro binding to brain homogenates
Binding of [125I]WYE-230949 to rat brain homogenates was saturable (Fig. 2) and
displaced by 10 mM iodophenpropit. Data was best fitted with a one-site binding
model yielding calculated values for Kd of 6.9¡1.3 nM and Bmax of
508.6¡34.9 fmol/mg protein (n58). Non-specific binding was linear and
represented 39¡3% of total binding at 6.6¡0.1 nM (n53).
Assessment of a Novel H3 Receptor Tracer
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In vivo SPECT time activity curve
Serial microSPECT scanning was performed in order to provide information on
the brain uptake of [125I]WYE-230949 and the dynamics of [125I]WYE-230949
washout in vivo. Cerebral uptake of [125I]WYE-230949 was relatively low (Fig. 3).
The maximum uptake of [125I]WYE-230949 was 0.14¡0.01% ID/ml in the first
12 min following injection of [125I]WYE-230949 (n55). The half-life of
[125I]WYE-230949 in rat brain was 45.4 min.
Ex vivo biodistribution and autoradiography
Ex vivo experiments were performed in both anaesthetised and conscious rats to
examine if the low brain uptake of [125I]WYE-230949 detected by SPECT imaging
could have been due to anaesthesia. Brain uptake was low in both conscious and
anaesthetised rats, the maximal amount measured being 0.11%ID/g of tissue at
30 min in anaesthetised rats. The brain uptake in anaesthetised rats was
significantly higher than in conscious rats at both time points, 0.11¡0.01%ID/g
vs. 0.06¡0.01%ID/g at 30 min and 0.06¡0.01 vs. 0.03¡0.003%ID/g at 120 min
(Fig. 4). In other organs minimal differences between conscious and anaesthetised
rats were observed. Overall uptake of [125I]WYE-230949 was less at 120 min than
30 min in all organs. The peak radioactivity measured in plasma was
4.04¡1.14%ID/g of tissue at 0.38¡0.02 min (n56) and in whole blood was
3.14¡0.26%ID/g of tissue at 0.50¡0.03 min (n56). The radioactive concentra-
tion in plasma and whole blood reached a plateau of approximately 0.3%ID/g of
tissue after 2 min (Fig. 5).
In areas with high histamine H3 receptor densities, autoradiography
demonstrated that there was higher specific binding at 120 min than at 30 min; in
the caudate (p50.03), substantia nigra (p50.002), core (p50.0002) and shell of
the nucleus accumbens (p50.006), posterior cortex (p50.02) and amgydala
Fig. 2. Representative saturation binding curve for [125I]WYE-230949. Total, non-specific and specific binding to rat brain homogenates are plotted with
the corresponding Scatchard plot.
doi:10.1371/journal.pone.0115876.g002
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(p50.003) (Table 1). However, the ratio of specific to non-specific binding was
low (less than 1.4) in all brain ROIs examined both in conscious and anaesthetised
rats (Table 1). In addition, in all cases of ex vivo autoradiography after
administration of [125I]WYE-230949 the pattern of [125I]WYE-230949
Fig. 3. High Resolution microSPECT/MRI imaging after intravenous injection of [125I]WYE-230949. (A) coronal (top), horizontal (middle) and sagittal
(bottom) slices showing the region of interest indicated on the T2* image (left column) and co-registration with the SPECT image (right column). (B) Time
activity curve of radioactivity measured in the region of interest (n55). *brain tissue density taken as 1.05 g/ml.
doi:10.1371/journal.pone.0115876.g003
Fig. 4. Percentage of injected [125I]WYE-230949 in different organs of (A) anaesthetised and (B) conscious rats measured ex vivo. *** p,0.001
compared to anaesthetised rats.
doi:10.1371/journal.pone.0115876.g004
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Fig. 5. Percentage of injected [125I]WYE-230949 in plasma and whole blood of anaesthetised rats
measured ex vivo. Data are from three animals at 5, 10, 20, 60 and 100 min, six animals at 0, 0.33, 0.66, 1,
2, 3, 7.5, 15, 45, 80 and 120 min and nine animals at 30 min following intravenous injection of [125I]WYE-
230949. Inset showing the update during the first 5 min following injection.
doi:10.1371/journal.pone.0115876.g005
Table 1. Target to cerebellum ratios in discrete regions of the rat brain following administration of [125I]WYE-230949 (n54 to 5 for all groups) determined by
ex vivo autoradiography.
30 min 120 min Statistical significance
Conscious Anaesthetised Conscious Anaesthetised
Caudate Putamen 1.17¡0.03 1.13¡0.03 1.32¡0.04 1.20¡0.04 * {
Amygdala 1.12¡0.04 1.10¡0.02 1.26¡0.03 1.16¡0.03 {{
Nucleus Accumbens (Core) 1.15¡0.03 1.12¡0.03 1.36¡0.03 1.24¡0.04 * {{{
Nucleus Accumbens (Shell) 1.17¡0.06 1.12¡0.02 1.33¡0.05 1.24¡0.04 {{
Substantia Nigra 1.10¡0.02 1.19¡0.03 1.26¡0.03 1.26¡0.04 {{
Posterior Cortex 1.18¡0.03 1.08¡0.03 1.26¡0.02 1.13¡0.03 *** {{
Anterior Cortex 1.15 ¡ 0.02 1.09¡0.03 1.16¡0.02 1.10¡0.02 *
Medial Cortex 1.22¡0.03 1.10¡0.03 1.21¡0.02 1.12¡0.02 ***
Thalamus 1.11¡0.02 1.10¡0.03 1.08¡0.02 1.09¡0.02 NS
Hippocampus 1.06¡0.02 1.08¡0.03 1.10¡0.02 1.08¡0.01 NS
Hypothalamus 1.13¡0.03 1.16¡0.03 1.18¡0.02 1.18¡0.03 NS
Choroid Plexus 2.68¡0.04 1.73¡0.06 2.66¡0.11 1.79¡0.10 ***
The cerebellum was used as the non-specific reference region.
*p,0.05,
***p,0.001 lower specific binding ratios in anaesthetised compared to conscious rats at both time points,
{p,0.05,
{{p,0.01,
{{{p,0.001 higher specific binding ratios at 120 minutes compared to 30 minutes in both conscious and anaesthetised rats, (mean¡S.E.M.), n54 to 5 for
all groups, data analysed by 2-way ANOVA.
doi:10.1371/journal.pone.0115876.t001
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distribution was more homogeneous compared with the heterogeneous pattern of
radioligand binding obtained from in vitro autoradiography (Fig. 6).
Ex vivo analysis of rat plasma and brain samples
HPLC analysis of rat plasma and brain was performed in order to determine
whether low brain uptake was due to the metabolism of [125I]WYE-230949 in
vivo. At both time points and in conscious and anaesthetised rats two metabolites
were detected in plasma, one polar metabolite (Peak A, RT52.58 min) and one
metabolite of intermediate lipophilicity (Peak B, RT53.84 min). Both of the
metabolites were less lipophilic than [125I]WYE-230949 (Peak C, RT57.89 min)
(Fig. 7). The amount of parent compound remaining in the plasma was greater at
30 min than at 120 min (p50.009; Table 2) and the ratio of polar to intermediate
metabolites increased with time both in conscious and anaesthetised rats.
In both conscious and anaesthetised rats two metabolites were also detected in
brain tissue: one polar and one intermediate metabolite, both of which were less
lipophilic than [125I]WYE-230949. There was more parent compound present in
the brains of conscious compared to anaesthetised rats at both time points
(p50.035). The amount of parent compound remaining in the brain was similar
at 30 min and 120 min after administration of [125I]WYE-230949 in anaesthetised
and conscious rats (Table 2). The ratio of polar to intermediate metabolites
Fig. 6. The regional distribution of [125I]WYE-230949 uptake in rat brain sections. Ex vivo autoradiograms show the distribution and regional levels of
radioactivity in the tissue at 30 or 120 min after administration of [125I]WYE-230949. In vitro autoradiograms show total and non-specific binding following
incubation with 5 nM [125I]WYE-230949 or 5 nM [125I]WYE-230949+5 mM iodophenpropit respectively. Note the relatively low level of binding in the
cerebellum, the reference region used to calculate region of interest specific binding ratios presented in Table 1 with higher binding in the substantia nigra,
nucleus accumbens, choroid plexus and pineal gland.
doi:10.1371/journal.pone.0115876.g006
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increased with time, and this was greater in conscious compared to anaesthetised
rats.
Discussion
The aim of these studies was to evaluate [125I]WYE-230949 and assess its potential
as a novel radionuclide imaging agent for histamine H3 receptors, having the
advantage of a longer radioactive half-life that could be exploited more widely
than the currently used C11-labelled ligands. WYE-230949 was successfully
Fig. 7. Representative HPLC radiochromatogram showing radiolabelled parent compound and
metabolites in rat plasma after [125I]WYE-230949 injection. Polar and intermediate metabolites are shown
as Peak A (RT52.58 min) and peak B (RT53.84 min), respectively. Peak C (RT57.89 min) co-eluted with
cold WYE230949 and was identified as parent compound, [125I]WYE-230949.
doi:10.1371/journal.pone.0115876.g007
Table 2. Percentage of parent compound detected in rat brain and plasma samples at 30 and 120 min following injection of [125I]WYE-230949.
30 min 120 min Statistical significance
Conscious Anaesthetised Conscious Anaesthetised
Brain 46¡2 (n54) 27¡4 (n53) 36¡6 (n54) 32¡5 (n53) *
Plasma 38¡9 (n56) 14¡2 (n54) 8¡5 (n54) 3¡3 (n54) {{
*p,0.05 lower % parent compound present in anaesthetised compared to conscious rats,
{{p,0.01, lower % parent compound present at 120 minutes compared to 30 minutes (mean ¡S.E.M.), data analyzed by 2-way ANOVA.
doi:10.1371/journal.pone.0115876.t002
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radiolabeled by electrophilic iododestannylation with good properties for imaging
such as high specific activity (,80 GBq/mmol), radiochemical yield (average 50%)
and purity (.99%).
Initial in vitro characterisation suggested [125I]WYE-230949 had promise as a
potential radionuclide imaging agent for the histamine H3 receptor. Using
standard methodology the experimentally determined logP and logD values for
[125I]WYE-230949 were 1.59 and 1.64 respectively, which are comparable with
other radiotracers that readily enter the brain such as [11C]raclopride (LogP 1.2)
and [11C]GSK189254 (LogD of 1.7) [32, 36]. Optimal logD and logP values for
blood brain barrier (BBB) penetration of radiotracers should lie between 1.0 and
3.5, with lower values favouring specific binding and higher values improving BBB
diffusion [37, 38]. With a low molecular weight of 468.52 g/mol, no hydrogen
bond donors and 5 nitrogen and oxygen atoms, [125I]WYE-230949 has
characteristics that are predictive of good BBB penetration [39].
[125I]WYE-230949 has high affinity (Kd of 6.9 nM) for the rat histamine H3
receptor in whole rat brain homogenates. A Bmax value of 509 fmol/mg protein in
whole rat brain is higher than previously reported values of rat histamine H3
receptor densities. For example, the Bmax determined using [
123I]iodoproxyfan in
rat striatum was 78 fmol/mg of protein [40], the Bmax of [
125I]iodophenpropit in
rat cortex was 268 fmol/mg of protein [41] and [3H]GSK189254 in rat cortex was
283 fmol/mg of protein [36]. It would be reasonable to expect that the Bmax in
whole brain would be lower that the Bmax in striatum due to the presence of low
density regions in the whole brain homogenate. It is not clear why our values are
higher. Our data suggests that a secondary binding site is unlikely as the data were
best fit with a one site binding model and the Scatchard plot was linear except for
an expected increased variability at very low bound values (Fig. 2).
In vitro autoradiography showed the binding of [125I]WYE-230949 was
heterogeneously distributed in rat brain and corresponded with known histamine
H3 receptor distribution, specifically, in cortex, striatum, nucleus accumbens and
substantia nigra [42, 43]. Non-specific binding sites as defined by the presence of a
high concentration of iodophenpropit was homogeneous, indicating selectivity
and specificity of [125I]WYE-230949 binding to histamine H3 receptors in rat
brain in vitro.
However, subsequent in vivo imaging studies were not supportive of
[125I]WYE-230949 as a potential radionuclide imaging agent for the histamine H3
receptor. Following intravenous administration in rats, brain uptake of
[125I]WYE-230949 was low, maximally measured as 0.14%ID/g during the first
12 min post injection by SPECT and distinct areas corresponding to the known
distribution of H3 receptors could not be reliably identified on the SPECT images.
Brain uptake was considerably less than other organs and compares poorly with
other radiotracers for the histamine H3 receptor. Uptake of [
125I]WYE-230949,
like many PET and SPECT histamine H3 radiotracers, was much higher in the
lung, kidney and liver, the later probably reflecting hepatic metabolism and renal
excretion [17, 20, 21]. [125I]WYE-230949 clearance from plasma and whole blood
was rapid reaching a concentration of 0.2 – 0.3%ID/g from 2 min onwards,
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suggesting low plasma binding. By comparison, brain uptake of [11C]JNJ-
10181457, was 1.38%ID/g in rats at 5 min post injection [20] while that of
[11C]GSK189254A was 9.0%ID/L a 20 min post injection in the porcine brain
[36]. Other radioiodinated histamine H3 receptor tracers have also shown higher
brain uptake, such as [123I]GR 190028, [123I]FUB271 and [123I]iodoproxyfan with
peak brain uptake values of about 0.6%ID/g, 1.2%ID/g and 1.5%ID/g, respectively
[16].
The low brain uptake of [125I]WYE-230949 could be due to a number of
factors. One factor could be the rapid metabolism of [125I]WYE-230949 in the
body. Indeed, there was rapid [125I]WYE-230949 metabolism in the brain and
plasma with less than 38% of parent compound remaining after 30 minutes in
plasma. This compares with 58% parent [11C]GSK189254 and 43% parent
[18F]fluoroproxyfan remaining in plasma at 30 minutes post injection [21, 36].
Metabolism of [125I]WYE-230949 proceeded in the plasma with less than 8%
remaining after 120 min, compared with 55% [11C]GSK189254 remaining after
90 min. A highly hydrophilic species with a short retention time was detected by
HPLC in tissue extracts suggesting deiodination of [125I]WYE-230949 in vivo
(Fig. 7). It is unlikely that these highly hydrophilic species would cross the BBB.
Therefore the presence of hydrophilic species in the brain could be explained by
metabolism occurring in the brain itself, although contamination of brain samples
by metabolites in the cerebral vessels cannot be excluded. By comparison, greater
than 80% parent [11C]JNJ-10181457 remained in the brain at 30 min post
injection, and 94% and 68% parent [18F]fluoroproxyfan remained at 30 and
120 min respectively [20, 21].
In addition to the rapid metabolism of [125I]WYE-230949, ex vivo
autoradiography revealed the regions with highest uptake of [125I]WYE-230949 to
be the choroid plexus and, when present in sections, the pineal gland. A similar
observation was noted after systemic administration of [125I]iodophenpropit [17].
In the pineal gland this may be due to [125I]WYE-230949 passing through the
incomplete BBB, and in the choroid plexus this could reflect deiodination of
[125I]WYE-230949 resulting in uptake of free radioactive iodide via the sodium-
iodide symporter [44]. The thyroid also had high uptake on static whole brain
SPECT images, again suggesting [125I]WYE-230949 was deiodinating in vivo. The
absolute amount of deiodination in the choroid plexus could not be determined
by autoradiography as 125I standards were not available and uptake of free
radioactive iodine in the thyroid was assessed qualitatively in a static SPECT
whole brain scan (S1 Fig.).
Other factors that could affect brain uptake include active transport
mechanisms such as P-glycoprotein (P-gp) mediated transport and plasma
protein binding, BBB penetration is a complex process making prediction of in
vivo brain uptake from in vitro assays challenging. Recent studies have highlighted
that measurement of lipophilicity should not be relied upon as a predictor of BBB
penetration [38, 45].
It should be noted that higher specific binding was present at 120 min
compared with 30 min after [125I]WYE-230949 administration in the caudate,
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amygdala, core and shell of the nucleus accumbens, substantia nigra and posterior
cortex, all regions previously shown to have high histamine H3 receptor densities.
The increase in specific binding over time indicates that some of the injected
[125I]WYE-230949 was binding to histamine H3 receptors in these regions
[42, 43], but not in sufficient quantities to permit SPECT imaging.
Radioligand brain uptake, distribution and metabolite studies were performed
in conscious as well as anaesthetised rats to rule out the possibility that anaesthesia
may have confounded the images obtained from microSPECT imaging of
[125I]WYE-230949. Brain uptake was lower in conscious rats (almost half that of
anaesthetised rats; Fig. 4) and therefore anaesthesia could not explain the low
brain uptake of [125I]WYE-230949. However, there was greater specific binding in
the caudate, core of the nucleus accumbens, anterior, medial and posterior
cortices and the choroid plexus in conscious rats, which may be explained by less
metabolism of [125I]WYE-230949 compared to anaesthetised rats at 30 and
120 min post injection. Isoflurane has unpredictable effects on drug metabolism
and radiotracer binding, for example it accelerates the rate of cytochrome P-450
reduction by NADPH inhibition of aminopyrine N-demethylation, it activates
aniline hydroxylation, increases binding of [3H]-(S)-citalopram to serotonin
transporters and decreases [125I]PE2I binding to dopamine transporters
[46, 47, 48]. Additionally, mean and local cerebral blood flow is dose dependently
increased during isoflurane anaesthesia in most brain regions [49, 50]. Taken
together these results reinforce previous work demonstrating that general
anaesthesia during small animal imaging can have important effects on uptake,
metabolism and binding of the radiotracer under investigation. Increasingly in
radiotracer development, in vivo imaging is being performed in anaesthetised
animals without any evaluation in conscious animals. Since anaesthesia has the
potential to confound in vivo imaging studies, our data supports performing
validation of potential radiotracers under both conditions if possible.
In conclusion, [125I]WYE-230949 is not a useful radiotracer for imaging rat
histamine H3 receptors in vivo due to low brain uptake, in vivo metabolism of the
parent compound and low specific binding.
Supporting Information
S1 Fig. MicroSPECT/MRI images showing low brain and high glandular uptake
following [125I]WYE-230949 injection. High uptake was observed in the thyroid,
Hardarian and exorbital lacrimal glands suggestive of radio-deiodination. The
glands are indicated on the microSPECT images by the white arrows; HG,
Hardarian gland; ELG, exorbital gland; Th, thyroid gland.
doi:10.1371/journal.pone.0115876.s001 (TIF)
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